ロード中...
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain
Synthesis inhibition is the basis for the treatment of type 1 Gaucher disease by the glucosylceramide synthase (GCS) inhibitor eliglustat tartrate. However, the extended use of eliglustat and related compounds for the treatment of glycosphingolipid storage diseases with CNS manifestations is limited...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The American Society for Biochemistry and Molecular Biology
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3269155/ https://ncbi.nlm.nih.gov/pubmed/22058426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M021261 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|